Elizabeth Martin, MD
Ophthalmology · Silverdale, WANPI 1609219021
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,200 of the $6,539 with a category attached, or 64.2%. Sight Sciences, Inc. accounts for 73.7% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $4,577, more than ten times the $38 reported in 2020.
Across 52 payments — averaging $125.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$5K
- AbbVie$383
- Alcon$366
- NEW World Medical,inc.$315
- Nova Eye, Inc.$206
- Tarsus Pharmaceuticals, Inc.$145
- plus $304 from 8 others
Across 42 payments — averaging $1985.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$83K
What the payments were for
- Speaking & faculty fees$4,20064%
- Food & beverage$2,33936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 11 | $4,820 |
| AbbVie(2 entities) | 13 | $383 |
| Alcon | 7 | $366 |
| NEW World Medical,inc. | 4 | $315 |
| Nova Eye, Inc. | 1 | $206 |
| Tarsus Pharmaceuticals, Inc. | 5 | $145 |
| Aerie Pharmaceuticals, Inc. | 1 | $94 |
| Glaukos Corporation | 2 | $46 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Biotissue Holdings Inc. | 1 | $24 |
| Thea Pharma Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $22 |
| Ivantis, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,539 in reported general payments places this provider in the 85th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 25 | $15,473 |
| RhopressaNetarsudil Mesylate | 23 | $15,131 |
| VyzultaLatanoprostene Bunod | 31 | $14,724 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $13,897 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $9,757 |
| Latanoprost | 481 | $6,986 |
| Prednisolone Acetate | 146 | $6,245 |
| Brinzolamide | 24 | $5,172 |
| Timolol Maleate | 162 | $4,591 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $4,182 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 182 | $4,153 |
| Brimonidine Tartrate | 208 | $4,113 |
| Travoprost | 21 | $2,960 |
| Ketorolac Tromethamine | 55 | $1,790 |
| Dorzolamide Hcl | 60 | $1,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $94 | $29,02943 claims |
| AbbVieLumigan | $383 | $15,47325 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $38 | $14,72431 claims |
| AlconSimbrinza | $366 | $9,75733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Silverdale
- Todd SchneidermanSilverdale$200K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.